<?xml version="1.0" encoding="UTF-8"?>
<p>In the Ebola epidemic, various strategies were used for the design of efficacy (i.e., Phase 3) trials for investigational vaccines [
 <xref rid="pmed.1002632.ref003" ref-type="bibr">3</xref>]. Some investigators argued for individually randomized controlled trials (iRCTs), while others argued for forms of cluster-randomized controlled trials (cRCTs) [
 <xref rid="pmed.1002632.ref004" ref-type="bibr">4</xref>,
 <xref rid="pmed.1002632.ref005" ref-type="bibr">5</xref>]. Later in the epidemic, rapidly declining disease incidence required changes to some trial designs. Ideally, principles and protocols based on scientific, ethical, and feasibility considerations should be drawn up in advance of an epidemic, facilitating expediency and trust for rapid, early implementation once an epidemic occurs.
</p>
